Back to Search Start Over

Onabotulinumtoxin A Treatment of Drooling in Children with Cerebral Palsy: A Prospective, Longitudinal Open-Label Study.

Authors :
Møller, Eigild
Pedersen, Søren Anker
Vinicoff, Pablo Gustavo
Bardow, Allan
Lykkeaa, Joan
Svendsen, Pia
Bakke, Merete
Source :
Toxins. Jul2015, Vol. 7 Issue 7, p2481-2493. 13p.
Publication Year :
2015

Abstract

The aim of this prospective open-label study was to treat disabling drooling in children with cerebral palsy (CP) with onabotulinumtoxin A (A/Ona, Botox®) into submandibular and parotid glands and find the lowest effective dosage and least invasive method. A/Ona was injected in 14 children, Mean age 9 years, SD 3 years, under ultrasonic guidance in six successive Series, with at least six months between injections. Doses and gland involvement increased from Series A to F (units (U) per submandibular/parotid gland: A, 10/0; B, 15/0; C, 20/0; D, 20/20; E, 30/20; and F, 30/30). The effect was assessed 2, 4, 8, 12, and 20 weeks after A/Ona (drooling problems (VAS), impact (0-7), treatment effect (0-5), unstimulated whole saliva (UWS) flow and composition)) and analyzed by two-way ANOVA. The effect was unchanged-moderate in A to moderate-marked in F. Changes in all parameters were significant in E and F, but with swallowing problems ≤5 weeks in 3 of 28 treatments. F had largest VAS and UWS reduction (64% and 49%). We recommend: Start with dose D A/Ona (both submandibular and parotid glands and a total of 80 U) and increase to E and eventually F (total 120 U) without sufficient response. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20726651
Volume :
7
Issue :
7
Database :
Academic Search Index
Journal :
Toxins
Publication Type :
Academic Journal
Accession number :
108526308
Full Text :
https://doi.org/10.3390/toxins7072481